Linio Biotech is a biotechnology platform company that is revolutionizing skin regeneration with its groundbreaking product, Tience®. With a commitment to enhancing the lives of individuals with skin defects and aging skin, the company has developed the world’s first cell-free tissue product through over a decade of intensive R&D efforts. Founded in 2017 and headquartered in Finland, Linio Biotech secured a noteworthy €4.20M Seed Round investment on November 22, 2023. This significant investment signifies the market's recognition of the potential of Tience® to disrupt the sector of regenerative aesthetics. The company's ambitious and competent international team is committed to propelling this innovative core technology to the global market, positioning Linio Biotech as a key player in the pivotal biotechnology industry.
No recent news or press coverage available for Linio Biotech .